High-Sensitivity Cardiac Troponin I Testing: SuperFlex Case Study and Clinical Value

Cardiac troponin is the recognized gold-standard biochemical marker for myocardial infarction, with 100% diagnostic sensitivity and 91% specificity in the evaluation of acute myocardial infarction (AMI), and a sustained elevation window that supports both early diagnosis and risk stratification. The development of high-sensitivity cardiac troponin I (hs-cTnI) assays now enables the detection of myocardial injury earlier than ever before — a critical advantage in the emergency department, where every hour matters.

1. Origin of Cardiac Troponin

Peripheral blood measurement of cardiac troponin for the diagnosis of myocardial infarction was first reported internationally in 1987. Within roughly a decade, cardiac troponin had largely replaced creatine kinase isoenzyme (CK-MB) as the gold-standard biochemical marker for AMI. Today, troponin plays an indispensable role in the screening, diagnosis, and prognostic assessment of acute myocardial infarction in patients presenting with chest pain.

2. Definition of Cardiac Troponin

Cardiac troponin (Tn) is a regulatory protein of muscle contraction, located on the thin filaments of the contractile apparatus and central to the regulation of myocardial contraction and relaxation. The troponin complex contains three isoforms: fast-twitch, slow-twitch, and cardiac troponin (cTn). The first two are associated with skeletal muscle, while cardiac troponin is found exclusively in cardiomyocytes. It is a complex composed of three subunits: troponin T (cTnT), troponin I (cTnI), and troponin C (cTnC).

Both cTnT and cTnI are cardiac-specific antigens. cTnI has a molecular weight of approximately 23.88 kDa and is released from the myofibrils when cardiomyocytes are damaged. Elevated serum cTn reflects myocardial cell injury, with both specificity and sensitivity superior to the conventional cardiac enzyme panel (myocardial enzyme profile).

3. Clinical Significance

Cardiac troponin is a specific marker of myocardial injury and necrosis and carries major clinical significance for the diagnosis and risk stratification of AMI. Elevated troponin values indicate myocardial injury and can be seen in acute myocardial infarction, unstable angina, pulmonary embolism, heart failure with shock, and other conditions that damage the myocardium — including pancreatitis, severe diabetic ketoacidosis, and connective tissue disease. The higher the value, the more extensive the injury.

In AMI patients, troponin begins to be released at 3–6 hours after symptom onset, peaks at 10–24 hours, and normalizes in 5–7 days for cTnI and 10–15 days for cTnT. Mild elevation may also be observed in some patients with renal insufficiency.

4. SuperFlex Platform: High-Sensitivity Cardiac Troponin I Assay

The SuperFlex fully automated chemiluminescence analyzer, paired with the high-sensitivity cardiac troponin I (hs-cTnI) reagent kit (magnetic microparticle chemiluminescence immunoassay), uses patented nano-scale magnetic beads (M-PVA) supplied by PerkinElmer Chemagen. The technology enables rapid magnetic response and highly efficient washing through reduced non-specific residue, while the large specific surface area enhances antigen-antibody binding. Combined with acridinium ester as the chemiluminescent label, the platform integrates the high sensitivity of direct chemiluminescence with the specificity of immunoassay.

5. Concordance Study with a multinational IVD brand

A concordance study was performed at a Class III Grade A hospital's clinical laboratory, comparing the SuperFlex hs-cTnI assay with a multinational IVD brand. The study included 20 cTnI-negative samples and 20 cTnI-positive samples spanning high, medium, and low concentrations. Two analyses were performed:

• Kappa concordance analysis between SuperFlex and the multinational IVD brand
• Overall concordance rate calculation for the same sample set

Results and Analysis

Of the 40 samples, 39 produced concordant results between the two methods, yielding an overall concordance rate of 97.5% — indicating excellent agreement between the SuperFlex hs-cTnI assay and the multinational brand reference method.

One discordant sample tested positive by SuperFlex but negative by the multinational IVD brand. After discussion with the laboratory director, both parties agreed that the result needed to be interpreted in conjunction with the clinical information, with the clinical diagnosis serving as the reference standard.

6. Patient Case: Early Detection of Acute Myocardial Infarction

Patient Information

The patient presented with chest tightness and fatigue for 5 days, plus chills and fever for 3 days. Symptoms began 5 days earlier after prolonged exertion and sun exposure, with chest tightness, palpitations, generalized fatigue, and muscle aches. The patient did not initially seek treatment, and symptoms did not improve with rest. Three days before presentation, chills, rigors, and subjective fever developed. The patient self-medicated with traditional remedies, with partial but transient relief. On the day before presentation, the patient developed dyspnea, nausea, vomiting, worsening chest tightness, palpitations, fatigue, and generalized body aches that did not resolve with rest.

Root-Cause Analysis

In acute myocardial infarction, troponin is released at 3–6 hours and peaks at 10–24 hours. In the early phase of this patient's MI, cTnI had not yet been released in large quantities, so the concentration increase was modest — leading to a negative result on the multinational IVD brand assay. The SuperFlex hs-cTnI assay, however, was able to detect the early cTnI elevation, demonstrating its ultra-high sensitivity and its capacity to detect rising troponin concentrations earlier and more promptly.

Suspected acute coronary syndrome (ACS) typically presents with acute chest discomfort — pain, pressure, tightness, or burning. An initial ECG should be completed within 10 minutes of first medical contact, and the initial ACS workup should classify patients into two groups based on the ECG result: STEMI (typically with persistent chest pain > 20 minutes) and non-ST-elevation ACS (NSTE-ACS). STEMI management is centered on minimizing total myocardial ischemic time, achieving reperfusion as early as possible, and restoring effective myocardial blood flow.

Evidence shows that in STEMI patients, if diagnosis and effective treatment are achieved within 1 hour of symptom onset (the golden hour), mortality can be reduced from 9% to 3%. If diagnosis and treatment are delayed to 3–4 hours, mortality rises by approximately 5-fold [1].

Conclusion

The SuperFlex fully automated chemiluminescence analyzer, paired with the high-sensitivity cardiac troponin I reagent kit, delivers high-sensitivity detection performance without compromising specificity. It is an ideal cardiac-marker testing system that helps clinicians identify myocardial-infarction patients earlier, clarifies the diagnostic pathway, shortens time to treatment, and better meets the need for rapid diagnosis in patients presenting with acute chest pain.